QQ客服 官方微博 反馈留言

浏览/检索结果: 共11条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序作者升序作者降序提交时间升序提交时间降序题名升序题名降序 Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 期刊论文 AUTOPHAGY, 2021, 卷号: 17 作者:  Klionsky, Daniel J.;  Abdel-Aziz, Amal Kamal;  Abdelfatah, Sara;  Abdellatif, Mahmoud;  Abdoli, Asghar 收藏  |  浏览/下载：278/0  |  提交时间：2021/05/31 Autophagosome  cancer  flux  LC3  lysosome  macroautophagy  neurodegeneration  phagophore  stress  vacuole   Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial 期刊论文 JAMA ONCOLOGY, 2018, 卷号: 4, 期号: 9 作者:  Goss, Glenwood D.;  Felip, Enriqueta;  Cobo, Manuel;  Lu, Shun;  Syrigos, Konstantinos 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05 Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers 会议论文 作者:  Isla, Dolores;  Min, Young Joo;  Ardizzoni, Andrea;  Gadgeel, Shirish;  Dupuis, Nicholas 收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05 Squamous cell carcinoma of the lung  NSCLC  afatinib   Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer 期刊论文 2017, 卷号: 2, 期号: 3, 页码: e000219 作者:  Blackhall Fiona;  Ross Camidge D;  Shaw Alice T;  Soria Jean-Charles;  Solomon Benjamin J 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/03 Alk  clinical trial  crizotinib  profile 1005   Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2015, 卷号: 33, 期号: 15 作者:  Soria, Jean-Charles;  Felip, Enriqueta;  Cobo, Manuel;  Lu, Shun;  Syrigos, Konstantinos N. 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05 A fatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial 会议论文 作者:  Gadgeel, Shirish;  Soria, Jean-Charles;  Felip, Enriqueta;  Cobo, Manuel;  Lu, Shun 收藏  |  浏览/下载：9/0  |  提交时间：2019/12/05 Lung cancer / Oncology   Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial. 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2015, 卷号: 33, 期号: 15 作者:  Gadgeel, Shirish M.;  Dols, Manuel Cobo;  Felip, Enriqueta;  Soria, Jean-Charles;  Lee, Ki Hyeong 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05 LUX-Lung 8: A Global Phase III Trial of Afatinib (A) vs Erlotinib (E) as Second-Line Treatment in Patients (Pts) With Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy 会议论文 作者:  Hirsh, Vera;  Gadgeel, Shirish;  Soria, Jean-Charles;  Felip, Enriqueta;  Cobo, Manuel 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05 Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial. 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2015, 卷号: 33, 期号: 15 作者:  Gadgeel, Shirish M.;  Dols, Manuel Cobo;  Felip, Enriqueta;  Soria, Jean-Charles;  Lee, Ki Hyeong 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05 Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial 期刊论文 LANCET ONCOLOGY, 2015, 卷号: 16, 期号: 8 作者:  Soria, Jean-Charles;  Felip, Enriqueta;  Cobo, Manuel;  Lu, Shun;  Syrigos, Konstantinos 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05